Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human adenovirus type 5 versus cisplatin intraperitoneal injection for malignant ascites
ChiCTR2100051250Phase 4Recruiting
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- Oct 2021
- Modality
- Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 4, open-label trial of Oncorine and cisplatin in malignant ascites (2 arms), sponsored by First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoint: Objective response rate. Started Oct 2021; status: recruiting.
02
Drugs
Oncorinecisplatin
03
Conditions
malignant ascites
Beyond the preview
Go deeper on ChiCTR2100051250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051250.